A hormone-receptor interaction weakens immunity. Targeting it could fight cancer. Scientists at UT Southwestern Medical ...

Orforglipron will be submitted to global regulatory authorities for the treatment of obesity or for weight loss by the end of ...

Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with ...

Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.

Cite this: Receptor for Advanced Glycation End Products: Its Role in Alzheimer's Disease and Other Neurological Diseases - Medscape - Mar 31, 2009. Disclosure: The authors have no other relevant ...

MTVA READ THE FULL MTVA RESEARCH REPORT Business Update DA-1726 48 mg Cohort Study Extended to Eight Weeks On August 6, 2025, MetaVia, Inc. (NASDAQ:MTVA) announced that the company has extended the 48 ...

Recently these monocyte-derived alveolar macrophages, or Mo-AMs, were identified as key drivers of lung fibrosis disease progression. However, the mechanisms of their pro-fibrotic behavior and ...